Unlock instant, AI-driven research and patent intelligence for your innovation.

Fusion peptide for inhibiting tumor growth and application thereof in preparing anti-tumor medicament

A technology for fusion of peptides and tumors, applied in the direction of hybrid peptides, peptides, specific peptides, etc.

Inactive Publication Date: 2013-06-05
CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] In summary, although there are reports about anti-tumor small peptides used in anti-tumor therapy in the prior art, they are all used alone or fused with protein transduction sequences or combined with cells highly expressed against tumor cells. The use of ligand fusion of anti-tumor peptides has not been seen to combine anti-tumor small peptides with protein transduction sequences and ligands for cell receptors highly expressed by tumor cells to simultaneously improve the bioavailability and target of anti-tumor small peptides. tropism report

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion peptide for inhibiting tumor growth and application thereof in preparing anti-tumor medicament
  • Fusion peptide for inhibiting tumor growth and application thereof in preparing anti-tumor medicament
  • Fusion peptide for inhibiting tumor growth and application thereof in preparing anti-tumor medicament

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] The synthesis of embodiment 1 polypeptide (PUMA) BH3, TAT-DV3 and TAT-DV3-BH3

[0040] Experimental results show that the targeted fusion peptide of (PUMA) BH3 domain can inhibit the growth of some tumor cells and exhibit certain anti-tumor activity. Therefore, a targeted fusion peptide containing (PUMA) BH3 domain and two reference polypeptides were synthesized from Shanghai Gill Biotechnology Co., Ltd. All synthetic peptides were purified by reverse-phase high-performance liquid chromatography with a purity of >95%. The amino acid sequence was verified by MALDI-TOF mass spectrometry analysis, and FITC was added to the N-terminus of each peptide. The names of the peptides are (PUMA)BH3, TAT-DV3 and TAT-DV3-BH3, and the sequences are shown in Table 1.

[0041] Table 1:

[0042]

Embodiment 2

[0043] Example 2 Fusion peptide TAT-DV3-BH3 inhibits cell growth experiment

[0044] Select 5 cell lines from known tumor cells overexpressing CXCR4: human colon cancer cell HCT116 P53+ / + and HCT116 P53- / - , human lung adenocarcinoma cell line GLC-82, human breast cancer cell line MDA-MA-231, human gastric cancer cell line SGC-7901, two non-tumor cell lines human embryonic lung fibroblast 2BS and human embryonic kidney fibroblast HEK293 . Two of the colon cancer cells were P53 wild-type HCT116 P53+ / + , and the other is p53-deleted HCT116 P53- / - ; If the peptide we synthesized induces cell apoptosis according to the PUMA (BH3) pathway as we imagined, then there should be no significant difference in the effect of the peptide on the two strains of cells, that is to say, the occurrence of apoptosis is related to that of P53. Existence is irrelevant. The above 7 kinds of human tumor cells were subjected to cell growth inhibition experiment with polypeptide TAT-DV3-BH3. For s...

Embodiment 3

[0048] Effect of embodiment 3 (PUMA) BH3, TAT-DV3 and TAT-DV3-BH3 on cell growth

[0049] HCT116 was added at 5000 cells / well P53+ / + 、HCT116 P53- / - and HEK283 cells were inoculated in a 96-well plate, and after 24 hours of culture, the original culture medium was sucked off, and (PUMA) BH3, TAT-DV3 and TAT-DV3-BH3 were added with a final concentration of 60 μM; then cultured for 72 hours, and the polypeptide containing Add 100 μL (including 10 μL of CCK-8) culture solution to each well, and continue to cultivate for 1 hr. Use a Bio-Rad 680 microplate reader to measure the absorbance at 450 nm and the reference wavelength at 630 nm to measure the absorbance of each well and the survival rate (%) =100×(A experimental group-A blank) / (A control group-A blank), the results are shown in Table 3, figure 2 .

[0050] Table 3 Effects of peptides with a concentration of 60 μM on cell viability

[0051]

[0052] The above results indicated that neither (PUMA)BH3 acting alone nor ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
control rateaaaaaaaaaa
Login to View More

Abstract

The invention discloses a fusion peptide for inhibiting tumor growth and an application thereof in preparing to anti-tumor medicament. The fusion peptide comprises a protein transduction sequence, a ligand sequence of a cell surface receptor sequence with high tumor cell expression and a small peptide with a sequence number of SEQ.ID.NO.3. Through fusion, the high-efficiency transduction capability to protein of the protein transduction sequence is maintained, and the targeting of transduction is also enhanced so as to ensure that anti-tumor small peptides efficiently and specifically enter a targeted cell. The fusion peptide improves the bioavailability and the targeting of anti-tumor peptide medicaments and reduces the probability that an organism generates an immunological reaction to the medicaments.

Description

technical field [0001] The invention relates to a fusion peptide for inhibiting tumor growth and the use of the fusion peptide in preparing antitumor drugs. Specifically, the present invention relates to a fusion peptide containing (PUMA) BH3 and its application in the preparation of antitumor drugs. Background technique [0002] Malignant tumors have become a major disease that threatens human health. Although the survival rate of malignant tumor patients has been greatly improved with the improvement of surgery, chemotherapy and radiotherapy, it still seriously threatens the life and health of patients. Traditional tumor chemotherapy has poor targeting and side effects on tumors. Finding and developing new therapeutic drugs with high-efficiency tumor-killing activity and tumor-targeting is an urgent requirement to conquer the stubborn disease of malignant tumors. Tumor biotherapy is a new treatment method after surgery, radiotherapy and chemotherapy, and has broad develo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00
Inventor 钱海利林晨刘勇军
Owner CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI